Patients with EGFR exon 20 insertion-positive NSCLC have historically faced limited targeted treatment options compared with those harboring more common EGFR mutations, leaving platinum-based chemotherapy as the frontline standard despite modest outcomes. Sunvozertinib (ZEGFROVY), an irreversible and selective EGFR inhibitor approved in the US and China for previously treated EGFR exon 20 insertion-positive NSCLC, is aiming to address this unmet need earlier in the treatment paradigm.

The Phase III WU-KONG28 trial marks a significant breakthrough as the first global randomized study to demonstrate positive results with a chemotherapy-free targeted monotherapy in the first-line setting for EGFR exon 20 insertion-positive NSCLC. The landmark findings, presented as a late-breaking abstract at ASCO 2026 and simultaneously published in the New England Journal of Medicine, position sunvozertinib as a potential new frontline treatment option for this challenging patient population. Key results are presented below:

Key Efficacy result: 

Safety result:

• The safety profile was manageable and consistent with previous studies.

• Drug-related treatment-emergent adverse events (TEAEs) leading to discontinuation occurred in 7.4% of patients.

• No drug-related fatal adverse events were reported.

• The overall tolerability profile was consistent with prior sunvozertinib experience, with no new safety concerns identified.

• Findings support an oral, single-agent targeted first-line strategy for the heterogeneous EGFR exon 20 insertion population, historically less responsive to earlier-generation EGFR TKIs.

KOL insights

“The WU-KONG28 study demonstrates that ZEGFROVY monotherapy yields superior antitumor efficacy compared to platinum-doublet chemotherapy, while maintaining a manageable safety profile and enhanced convenience. These findings support the potential to usher the first-line treatment of EGFR exon20ins NSCLC into a chemotherapy-free era, providing global patients a more precise single-agent targeted therapeutic option.” –Expert Opinion

“This is the first randomized study demonstrating that an oral drug, sunvozertinib, is superior to the historical standard of care, which is chemotherapy-based treatment for this hard-to-treat population. If it receives approval as first-line therapy, patients with this mutation could start with a reasonably well-tolerated pill and have all the convenience of oral therapy prior to moving to chemotherapy-based combinations.”–Expert Opinion

Conclusion-

Despite the transformative impact of EGFR-targeted therapies over the past two decades, patients with EGFR exon 20 insertion-positive NSCLC continue to face limited treatment options, with platinum-based chemotherapy remaining the predominant first-line standard of care. This underscores a significant unmet need for targeted therapies that combine robust efficacy, favorable tolerability, and the convenience of oral administration.

The broader EGFR-mutated NSCLC market was valued at approximately USD 3 billion in 2025 and is projected to grow significantly through 2036. While approved EGFR TKIs including erlotinib, gefitinib, afatinib, dacomitinib, and osimertinib have transformed outcomes for patients with common EGFR mutations, therapeutic progress in the EGFR exon 20 insertion setting has lagged behind. The landscape is now evolving rapidly following the approval of sunvozertinib in 2025, intensifying competition with established players such as amivantamab. In parallel, emerging next-generation agents including furmonertinib and zipalertinib are advancing through clinical development, signaling a more dynamic and increasingly competitive future for the EGFR exon 20 insertion treatment market.